No Data
Tianjin Ringpu Bio-Technology (300119.SZ): Cumulatively repurchased 1.1329% of shares.
On January 2nd, Gelonghui reported that Tianjin Ringpu Bio-Technology (300119.SZ) announced that as of December 31, 2024, the company has cumulatively repurchased 5,277,751 shares of its own stock through centralized bidding, accounting for 1.1329% of the company's current total share capital. The lowest transaction price was RMB 18.30 per share, the highest transaction price was RMB 19.49 per share, and the total amount paid was RMB 99,988,049.99 (excluding transaction fees). This repurchase complies with the company's repurchase plan and relevant laws and regulations.
Is Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Recent Stock Performance Tethered To Its Strong Fundamentals?
Tianjin Ringpu Bio-Technology (300119.SZ) plans to spend 0.104 billion yuan to acquire a 56.31% stake in Zhongrui Supply Chain, enhancing the layout of the pet health sector.
Tianjin Ringpu Bio-Technology (300119.SZ) announced that the company intends to acquire Ruipai for 0.104 billion yuan using its own funds or self-raised funds...
Tianjin Ringpu Bio-Technology (300119.SZ) plans to change the company name to Tianjin Ringpu Bio-Technology Co., Ltd.
Tianjin Ringpu Bio-Technology (300119.SZ) announced that the company plans to change its Chinese name from “Tianjin Ringpu Bio-Technology Co., Ltd...”
tianjin ringpu bio-technology (300119.SZ): has repurchased 1.13% of the shares.
Glory Hong Kong, December 2 – tianjin ringpu bio-technology (300119.SZ) announced that as of November 30, 2024, the company has repurchased a total of 5,277,751 shares through centralized bidding trade, accounting for 1.1329% of the company's current total share capital. The lowest transaction price was 18.30 yuan/share, the highest transaction price was 19.49 yuan/share, and the total amount paid was 99.988 million yuan (excluding transaction fees).
Tianjin Ringpu Bio-Technology (300119.SZ): Obtained a new veterinary drug registration certificate.
On November 28, Glonghui reported that tianjin ringpu bio-technology (300119.SZ) announced that according to the "Regulations on Veterinary Drugs" and "Measures for the Registration of Veterinary Drugs", tianjin ringpu bio-technology Co., Ltd. and its subsidiary, ringpu (tianjin) bio-pharmaceutical Co., Ltd., shanxi ruixiang bio-pharmaceutical Co., Ltd., and hubei longxiang pharmaceutical technology Co., Ltd. recently obtained the "New Veterinary Drug Registration Certificate" issued by the Ministry of Agriculture and Rural Affairs. The related new veterinary drugs are hydrochloride vonipinol dihydrate and hydrochloride vonipinol dihydrate soluble powder. In the context of the global antibiotic reduction initiative, hydrochloride vonipinol dihydrate soluble powder is also related to truncated side.
Earnings Working Against Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Share Price
No Data
